Addex Pharmaceuticals’ (Addex) ADX10059 has demonstrated significant potential in a non-human primate model of Parkinson’s disease levodopa induced dyskinesia (PD-LID).
ADX10059 is an allosteric inhibitor – a negative allosteric modulator (NAM) – of a glutamate receptor subtype called metabotropic glutamate receptor 5 (mGluR5).
Reportedly, in a recently completed study using the MPTP primate model, all doses of ADX10059 abolished levodopa induced dyskinesia in the first hour after levodopa administration. The 10mg/kg and 30mg/kg doses of ADX10059 significantly reduced dyskinesia in the first two hours after levodopa dosing.
Addex has also reported during its July R&D Day that in rats, ADX10059 showed a dose dependent effect in reducing catalepsy induced by haloperidol, a rodent model of Parkinson’s disease.
In addition, the data from Addex and other researchers showed that mGluR5 inhibition has therapeutic potential in multiple indications. Addex has prioritised development in GERD and migraine; others are pursuing PD-LID, Fragile X syndrome and neuropathic pain.
The company is expecting the phase IIb data for ADX10059 in the fourth quarter of 2009 for GERD, and the first quarter of 2010 for migraine prevention.